Next |
home / stock / iova / iova message board
Subject | By | Source | When |
---|---|---|---|
Citing feedback, the company announced that the design | jondoeuk | investorshub | 07/10/2023 5:02:29 PM |
$IOVA Price gaining | Watts Watt | investorshub | 07/10/2023 5:37:07 AM |
Do we have a winner?Turn around time? | jondoeuk | investorshub | 07/08/2023 7:59:28 AM |
$IOVA Lets go go go go... Up up and away we go. | Watts Watt | investorshub | 07/05/2023 10:58:06 PM |
$IOVA bulls and bears | jondoeuk | investorshub | 07/05/2023 5:31:05 PM |
(OT): The importance of CD4+ T-cells https://aacrjournals.org/clincancerres/arti | jondoeuk | investorshub | 07/05/2023 12:26:26 AM |
$IOVA The now | Watts Watt | investorshub | 06/30/2023 9:57:52 PM |
where is the squeeze? | ClayTrader | investorshub | 06/30/2023 7:49:12 PM |
Price now | jondoeuk | investorshub | 06/25/2023 12:55:42 PM |
In addition, use a manufacturing process that promises | jondoeuk | investorshub | 06/25/2023 12:09:45 AM |
They combined the CRISPRomics platform with CRISPR2 tech, | jondoeuk | investorshub | 06/25/2023 12:08:01 AM |
(OT): KSQ Therapeutics is working on gene-edited TIL | jondoeuk | investorshub | 06/25/2023 12:04:59 AM |
MomentumIts now | ClayTrader | investorshub | 06/24/2023 11:22:11 PM |
ImmuT Finder is a novel T-cell immunoregulatory target | jondoeuk | investorshub | 06/23/2023 11:30:19 PM |
Preclinical data https://ascopubs.org/doi/10.1200/JCO.2021.39.15 suppl.e14506 https://aacrjournals.o | jondoeuk | investorshub | 06/23/2023 11:23:58 PM |
(OT): GRIT Bio was founded in 2019 and | jondoeuk | investorshub | 06/23/2023 11:19:55 PM |
$IOVA we got news | Porterhouse10 | investorshub | 06/17/2023 1:49:41 AM |
$IOVA Price gaining | jondoeuk | investorshub | 06/15/2023 11:37:04 PM |
$IOVA The now | dinogreeves | investorshub | 06/15/2023 1:54:42 AM |
what do you make of this data? | jondoeuk | investorshub | 06/14/2023 11:00:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 ...
2024-04-28 14:44:00 ET There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deepl...
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biote...